The National Myelodysplastic Syndromes Natural History Study Aim: To collect samples that will be used to create a database, which will be used to better understand how MDS changes over time and may lead to better ways to prevent, detect and treat MDS.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone- Sensitive Prostate Cancer.
A phase II Study of Iplimumab,Cabozantinib and Nivolumab in rare Genitourinary cancers (ICONIC).
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met+, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus cCRT Followed by Tislelizumab Versus cCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
Aim: The goal of this trial is to find out if an experimental medication called Savolitinib in combination with Osimertinib will work and be safe for the treatment of metastatic Lung Cancer in patients who have an EGFRm+ and MET+ mutation.
Aim: To compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.
Integration of Immunotherapy into Adjuvant therapy for resected NSCLC.
Aim: To examine lung cancer patients’ surgically removed tumors for certain genetic changes, and possibly refer there patients to a treatment study with drugs that may specifically target tumors that have these genetic changes.
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence.